GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1.

Summary: GHRP-2 directly attenuates Atrogin-1 and MuRF1 mRNA levels in myocytes through ghrelin receptors, potentially reducing muscle atrophy.

Link: ScienceDirect

Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells.

Summary: GHRP-6 stimulates growth hormone secretion in pituitary somatotrophs by activating the phosphatidylinositol (PI) second messenger system, supporting earlier findings that PKC and Ca2+ play central roles in mediating its effects.

Link: Bioscientifica

Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms

Summary: GHRP-6 administration in parallel to doxorubicin prevents myocardial and extra-myocardial damage, preserving systolic function and reducing morbidity and mortality in healthy rats.

Link: Frontiers

GHRP-6 induces a biphasic calcium response in rat pituitary somatotrophs.

Summary: GHRP-6 induces a biphasic calcium response in rat somatotrophs, with the first phase likely due to intracellular calcium mobilization and the second phase a PKC-dependent process.

Link: ScienceDirect

The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular adenosine 3′,5′-monophosphate (cAMP) levels and GH secretion in ovine and rat somatotrophs.

Summary: GHRP-2 and GHRP-6 both increase intracellular cAMP levels and cause GH release in sheep somatotrophs, while GHRP-6 causes GH release without increasing cAMP levels, suggesting different receptors.

Link: Bioscientifica

A polypeptide-mediated synthesis of green fluorescent gold nanoclusters for Fe3+ sensing and bioimaging.

Summary: GHRP-6-Au NCs, a green fluorescent gold nanocluster, can effectively detect trace Fe3+, making them a highly sensitive sensor for Fe3+ sensing and bioimaging applications.

Link: ScienceDirect

Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers.

Summary: GHRP-6 has a bi-exponential disposition, with a distribution and elimination half-life of 7.6  1.9 min and 2.5  1.1h, and dose dependence with a noticeable increase in AUC with administered dose.

Link: ScienceDirect

Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature.

Summary: Oral GHRP-6 administration effectively stimulates growth hormone secretion in children with normal short stature, similar to the effect of intravenous GH-releasing hormone.

Link: Oxford Academic

Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.

Summary: GHRP-6 and GHRH together can effectively increase growth hormone secretion in children with neonatal pituitary stalk transection, potentially serving as a diagnostic tool.

Link: Oxford Academic

Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.

Summary: GHRP-6-induced growth hormone secretion in man occurs through a non-GHRH-dependent mechanism, with pyridostigmine and insulin-induced hypoglycemia increasing this response.

Link: Oxford Academic